2009, Number 1
Rev Med Inst Mex Seguro Soc 2009; 47 (1)
García-Álvarez JL, Sánchez-Tovar M, García-Vigil JL
PDF size: 345.02 Kb.
ABSTRACTObjective: to evaluate if used of medication with antioxidants, antiplatelets, statins and modulators of inflammation reduces effectively the risk of presenting a cardiovascular disease (CVD).
Methods: a search on clinical trials (randomized, double blind and controlled clinical studies) in which the use of antioxidants, antiplatelets, statins and modulators of inflammation were investigated for the primary and secondary prevention of CVD. The selected studies were analyzed by a systematic revision, applying the meta-analysis.
Results: 20 studies were included. In the subgroup of vitamin E 3623 events of the non fatal acute myocardial infarction (AMI) appeared, RR = 1 (0.93-1.06) IC 95 %, p = 0.01. In the subgroup of statins 2795 events of non fatal acute myocardial infarction (AMI) appeared, RR = 0.68 (0.63-0.73) IC 95 %, p = 0.02. In the subgroup of antiplatelets 1199 events of non fatal AMI appeared, RR = 0. 91 (0.81-1.02) IC 95 %, p = 0.42. In the subgroup of ω-3 fatty acids 434 events of the non fatal AMI appeared, RR = 0.93 (0.76-1.13) IC 95 %, p = 0.002.
Conclusions: vitamin E did not show any benefit, in comparison with the antiplatelets, statins, and ω-3 fatty acids.